Clinical Trials | February 17, 2026
Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD
Duvakitug was well tolerated and safety was consistent with the induction study
Duvakitug was well tolerated and safety was consistent with the induction study
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe
Iberdomide has the potential to be the first approved CELMoD agent
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
Subscribe To Our Newsletter & Stay Updated
